- Home
- REPL vs DIAX Comparison
REPL vs DIAX Comparison
Compare REPL & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- DIAX
- Stock Information
- Founded
- REPL 2015
- DIAX 2005
- Country
- REPL United States
- DIAX United States
- Employees
- REPL N/A
- DIAX N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- DIAX Finance Companies
- Sector
- REPL Health Care
- DIAX Finance
- Exchange
- REPL Nasdaq
- DIAX Nasdaq
- Market Cap
- REPL 547.0M
- DIAX 521.1M
- IPO Year
- REPL 2018
- DIAX N/A
- Fundamental
- Price
- REPL $5.56
- DIAX $14.48
- Analyst Decision
- REPL Buy
- DIAX
- Analyst Count
- REPL 10
- DIAX 0
- Target Price
- REPL $8.25
- DIAX N/A
- AVG Volume (30 Days)
- REPL 24.2M
- DIAX 96.6K
- Earning Date
- REPL 08-07-2025
- DIAX 01-01-0001
- Dividend Yield
- REPL N/A
- DIAX 7.93%
- EPS Growth
- REPL N/A
- DIAX N/A
- EPS
- REPL N/A
- DIAX N/A
- Revenue
- REPL N/A
- DIAX N/A
- Revenue This Year
- REPL N/A
- DIAX N/A
- Revenue Next Year
- REPL $194.05
- DIAX N/A
- P/E Ratio
- REPL N/A
- DIAX N/A
- Revenue Growth
- REPL N/A
- DIAX N/A
- 52 Week Low
- REPL $2.68
- DIAX $12.80
- 52 Week High
- REPL $17.00
- DIAX $15.12
- Technical
- Relative Strength Index (RSI)
- REPL 44.05
- DIAX 60.39
- Support Level
- REPL $4.49
- DIAX $14.28
- Resistance Level
- REPL $6.39
- DIAX $14.41
- Average True Range (ATR)
- REPL 0.77
- DIAX 0.11
- MACD
- REPL 0.09
- DIAX 0.01
- Stochastic Oscillator
- REPL 48.77
- DIAX 84.78
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.